LONDON (Reuters) - An experimental antidepressant from AstraZeneca Plc and Targacept Inc failed to meet the goal of changing a key depression rating score in the first of a series of pivotal clinical trials, a setback for both firms…….click here to continue reading
Targacept Inc. and AstraZeneca have enrolled the first patient in a Phase III program for depression drug candidate TC-5214, which showed positive results in Phase II testing as an add-on therapy for patients who did not respond well to prior treatment with another antidepressant, citalopram…….click here to continue reading
Pharmaceutical company AstraZeneca PLC says its schizophrenia drug Seroquel XR has been recommended by European regulators as an add-on treatment for depression…….click here to continue reading
Targacept could get $1.24B and royalties as it teams up with AstraZeneca on depression drug……click here to continue reading
Targacept Inc. on Thursday struck a deal potentially worth more than $1 billion to develop a depression drugs with AstraZeneca PLC, one of the world’s largest drugmakers…….click here to continue reading